Engineered immune cells battle stubborn lymphoma in new trial

NCT ID NCT03105336

Summary

This study tested whether a treatment called axicabtagene ciloleucel, a type of CAR-T cell therapy, could help people with slow-growing non-Hodgkin lymphoma that had come back or stopped responding to other treatments. It involved 159 participants whose cancer had progressed after at least two prior lines of therapy. The approach involved collecting a patient's own immune cells, genetically modifying them to better target cancer, and then infusing them back into the patient.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INDOLENT NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona, 85234, United States

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, 69495, France

  • Centre Hospitalier Régional Universitaire de Lille

    Lille, 59037, France

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington, 98109, United States

  • Georgetown Lombardi Comprehensive Cancer Center

    Washington D.C., District of Columbia, 20007, United States

  • H Lee Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Hackensack University Medical Center - John Theurer Cancer Center

    Hackensack, New Jersey, 07601, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Ohio State University Medical Center

    Cleveland, Ohio, 44106, United States

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • University of California Los Angeles

    Los Angeles, California, 90095, United States

  • University of Miami Hospital and Clinics

    Miami, Florida, 33136, United States

  • University of Rochester Medical Center (URMC)

    Rochester, New York, 14642, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

Conditions

Explore the condition pages connected to this study.